Figure 6

Ability of SAMHD1 oligomerization variants to restrict HIV-1. PMA-treated human monocytic U937 cells stably expressing the indicated SAMHD1 variant (A) were challenged with increasing amounts of HIV-1-GFP (B). As control, U937 cells stably transduced with the empty vector LPCX were challenged with HIV-1-GFP. Similar results were obtained in three independent experiments and a representative experiments is shown. (C) Quantification of dNTP levels on PMA-treated U937 cells expressing the indicated SAMHD1 variants was performed by a primer extension methodology, as previously described [31].